[Skip to Navigation]
Sign In
December 28, 2021

Omitted Nonauthor Collaborators

JAMA Intern Med. 2022;182(2):239. doi:10.1001/jamainternmed.2021.7668

In the Original Investigation titled, “Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial,”1 published online October 7, 2021, the names of 3 investigators were omitted from Supplement 3. Phyllis Suen, MD, John Flynt, MD, and Michael Krzyzak, MD, of Staten Island University Hospital, Northwell Health, Staten Island, New York, have been added. This supplement has been corrected online.

Spyropoulos  AC, Goldin  M, Giannis  D,  et al; HEP-COVID Investigators.  Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial.   JAMA Intern Med. Published online October 7, 2021. doi:10.1001/jamainternmed.2021.6203PubMedGoogle Scholar